Global Information
회사소개 | 문의 | 위시리스트

당뇨병성 말초신경병증 : 세계 임상시험 리뷰

Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2019

리서치사 GlobalData
발행일 2019년 05월 상품 코드 302385
페이지 정보 영문 169 Pages
가격
US $ 2,500 ₩ 2,973,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,947,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,920,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


당뇨병성 말초신경병증 : 세계 임상시험 리뷰 Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2019
발행일 : 2019년 05월 페이지 정보 : 영문 169 Pages

당뇨병성 말초신경병증(Diabetic Peripheral Neuropathy) 치료제 임상시험의 최신 동향에 대해 분석했으며, 질환 개요, 지역 및 주요 국가의 임상시험 상황, 진행 상황별 임상시험 데이터, 피험자 모집 상황, 유망한 스폰서, 각 기업 및 연구기관의 임상시험 프로파일 등의 정보를 전해드립니다.

본 보고서 개요

각 지역의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 아시아태평양 지역 주요 5개국의 임상시험 건수
    • 유럽 주요 5개국의 임상시험 건수
    • 북미 주요 국가의 임상시험 건수
    • 중동 및 아프리카 주요 5개국의 임상시험 건수
    • 중남미 주요 5개국의 임상시험 건수

G7 국가의 임상시험 건수 : 대사이상 치료제 임상시험에서 당뇨병성 말초신경병증의 비율

G7 국가의 단계별 임상시험 건수

G7 국가의 임상시험 건수 : 진행 상황별

E7 국가의 임상시험 건수 : 대사이상 치료제 임상시험에서 당뇨병성 말초신경병증의 비율

E7 국가의 단계별 임상시험 건수

E7 국가의 임상시험 건수 : 진행 상황별

단계별 임상시험 건수

  • 진행중인 임상시험 : 단계별

진행 상황별 임상시험 건수

임상시험 목표 달성 상황

일정기간에 채용된 피험자

스폰서 종류별 임상시험 건수

유망한 스폰서

당뇨병성 말초신경병증 치료제 임상시험에 참여하고 있는 주요 기업

유망한 약제

최신 임상시험 뉴스

임상시험 프로파일 개요

부록

KSM 16.08.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Diabetic Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*

List of Figures

  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Diabetic Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • GlobalData Methodology

GlobalData's clinical trial report, "Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Peripheral Neuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • List of Tables
  • List of Figures
  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Diabetic Peripheral Neuropathy Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Diabetic Peripheral Neuropathy
  • Apr 18, 2019: Robust analgesic activity of Aptinyx's NYX-2925 in advanced DPN patients revealed through further analysis of data from phase 2 study
  • Mar 28, 2019: Aptinyx to present detailed results from phase 2 painful DPN study of NYX-2925 at American Pain Society Scientific Meeting
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source
Back to Top
전화 문의
F A Q